Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Dealmaking In The Wake Of Changing Regulatory And Reimbursement Decisions

This article was originally published in Start Up

Executive Summary

As big drugmakers move wholeheartedly into oncology, changing regulatory and reimbursement standards have dramatic implications for dealmaking - especially for smaller venture-backed start-ups who hope to sign lucrative alliances or M&A deals with deeper-pocketed partners.

You may also be interested in...



START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In

In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."

START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In

In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."

What New Cancer Pathway Programs Mean For The Drug Industry

New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel